These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36087240)

  • 1. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.
    Arnold N; Koenig W
    Curr Cardiol Rep; 2022 Nov; 24(11):1657-1667. PubMed ID: 36087240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
    Warden BA; Duell PB
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
    Sinning D; Landmesser U
    Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
    Scheen AJ; Wallemacq C; Lancellotti P
    Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
    Katsiki N; Vrablik M; Banach M; Gouni-Berthold I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
    Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
    Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
    Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
    Hadjiphilippou S; Ray KK
    Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease.
    Tomlinson B; Chow E; Chan P; Lam CWK
    Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1353-1361. PubMed ID: 35025707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
    Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
    Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
    Soffer D; Stoekenbroek R; Plakogiannis R
    J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
    German CA; Shapiro MD
    BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
    Smith KW; White CM
    J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclisiran-New hope in the management of lipid disorders?
    Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
    J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.